Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Emergence of a new glucoregulatory mechanism for glycemic control with dapagliflozin/exenatide therapy in type 2 diabetes
Clinical Update 8/28/2018 Chocolate for the Heart
Progressing K-554, a potential first-in-class non-incretin peptide for metabolic disease, to Phase 1 studies, with early data expected H2 2026 Kallyope, a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally, announced the Companys strategic priorities for 2026
Melanotan II dosage for womens libido enhancement
US$ 26.59
US$ 28.74
US$ 25.02
US$ 28.04
US$ 24.35
